ABSTRACT. Burgeoning estimates of the prevalence of childhood attention-deficit/hyperactivity disorder (ADHD) raise the possibility of a widespread risk factor. We seek to assess whether artificial food colorings (AFCs) contribute to the behavioral symptomatology of hyperactive syndromes. We searched ten electronic databases for double-blind placebo-controlled trials evaluating the effects of AFCs. Fifteen trials met the primary inclusion criteria. Meta-analytic modeling determined the overall effect size of AFCs on hyperactivity to be 0.283 (95% CI, 0.079 to 0.488), falling to 0.210 (95% CI, 0.007 to 0.414) when the smallest and lowest quality trials were excluded. Trials screening for responsiveness before enrollment demonstrated the greatest effects. Despite indications of publication bias and other limitations, this study is consistent with accumulating evidence that neurobehavioral toxicity may characterize a variety of widely distributed chemicals. Improvement in the identification of responders is required before strong clinical recommendations can be made. J Dev Behav Pediatr 25: [423][424][425][426][427][428][429][430][431][432][433][434] 2004. Index terms: attention-deficit/hyperactivity disorder, artificial food colorings, complementary and alternative medicine.
BACKGROUND
Approximately 3-10% of school-age children suffer from attention-deficit/hyperactivity disorder (ADHD). [1] [2] [3] Impaired relationships with family and peers, decreased academic achievement, and heightened risk for later drug abuse are some psychosocial costs of this disorder. 1, 4 Sufferers have more than double the median health care costs of their peers 5 and may cost school systems an additional 3 billion dollars per year. 1 Common treatments include behavioral therapy and pharmacotherapy with psychostimulants.
Because of concern about the safety of drugs, clinicians and families have for some time been reaching for alternative treatments, such as the Feingold Diet (FD), which eliminates a variety of artificial food colors (AFCs), naturally occurring salicylates, and artificial flavors and particular preservatives. Although surveys have identified widespread use of dietary treatments, 6, 7 physicians underestimate the prevalence of such alternative therapies because they overestimate parents' willingness to disclose their use. 8, 9 Controlled trials of the FD and of the effects of substances excluded from the FD first began to be published in 1976. 10, 11 Before long, laboratory work began to suggest that azo and fluorescein dyes, which make up the majority of AFCs, may affect motor systems in mammals through dopamine pathways. [12] [13] [14] [15] [16] [17] Many qualitative reviews and one meta-analysis have addressed the effects of either the FD or specific foodstuffs excluded from it, such as AFCs. Qualitative reviews have generally been discordant and contentious, though a panel sponsored by the National Institutes of Health in 1982 fashioned a compromise, acknowledging that controlled trials ''did indicate a limited positive association between 'the defined diets' and a decrease in hyperactivity.'' 41 In their meta-analysis of the effect of the FD on hyperactivity, Kavale and Forness included trials of hyperactive and nonhyperactive children. 42 They folded together trials of the FD, trials of variant diets eliminating a variety of foodstuffs, and trials in which subjects were challenged with individual foodstuffs, including AFCs. Their initial analysis included prospective, retrospective, cross-sectional, blind, and nonblind controlled trials that enrolled both hyperactive and nonhyperactive children and employed many categories of outcomes. The authors concluded that placement of children on the FD was associated with a statistically nonsignificant improvement of one-tenth of a standard deviation (SD). In a subanalysis, challenge with substances excluded from the FD (including AFCs) resulted in a statistically nonsignificant worsening of one-twentieth of a SD. The breadth of those authors' inclusion criteria, their oversight of several relevant trials, the subsequent publication of additional relevant trials, and other limitations of their study call for focused consideration of whether AFCs promote symptoms of hyperactivity.
OBJECTIVES
We wish to evaluate whether AFCs contribute to the symptomatology of childhood hyperactivity in children diagnosed with hyperactive syndromes, as measured on behavioral rating scales. Additionally, we propose three subhypotheses whose confirmation would either help explain the heterogeneity of prior trials' results, facilitate identification of responders to AFCs, or aid in design of future trials.
First, we propose that parents and teachers differ in their reports of responsiveness to AFCs, as teachers may be more likely to report hyperactivity than parents in pharmacotherapy trials. 43 Second, on the grounds that responsive children could ideally be identified without subjecting them to long, complex, blinded trials, we suggest that open trial and parental report can be employed as screening methods to identify potentially responsive children.
Third, we propose that subjects whose diagnosis of hyperactivity was assigned through comprehensive, rigorous evaluation have greater responsiveness to AFCs than do subjects who either were diagnosed more informally or lack a diagnosis of hyperactivity altogether. Our proposition reflects several investigators' suggestion [44] [45] [46] that hyperactive and control children fundamentally differ in their physiological responses to AFCs and implies that certainty of diagnosis would be predictive of response to AFCs.
METHODS

Inclusion Criteria
We searched for all double-blind placebo-controlled trials addressing a proposed relationship between consumption of AFCs and behavioral change in children with a diagnosis of hyperactivity. Randomization and employment of any of several reversal designs 47 were acceptable means of allocation compatible with maintenance of double-blind conditions, which reduce the risk of several types of bias. 48 Trials had to study subjects under 18 years of age and, to be eligible for our primary analysis, enroll children who met diagnostic criteria described at the foot of Table 1 . These criteria were chosen as encompassing a spectrum of illness variously labeled over time minimal brain dysfunction, hyperkinesis, hyperkinetic reaction, hyperactivity, attention deficit disorder, and ADHD. Since few investigators actually distinguished between the currently recognized hyperactive, inattentive and combined subtypes of the syndrome, we could not incorporate such a distinction in our study. Subjects may have previously been screened for responsiveness to either AFCs or the FD. A trial would be excluded if its subjects had participated in another included trial. For a secondary analysis aimed at addressing our subhypotheses, we included trials which evaluated whether AFCs provoke hyperactivity symptoms in nonhyperactive children (Table 2) .
Trials had to employ an intervention that could isolate the effects of AFCs. Investigators could either 1) challenge hyperactive children with AFCs or placebo or 2) submit subjects to blinded diets with or without AFCs.
We included a wide variety of behavioral outcome measures quantifying hyperactive behavior (Table 1) , including all examples of the Conners Parent Teacher Questionnaire (CPTQ), 49 whose 10 items are common to the longer parents' (CPQ) and teachers' (CTQ) scales. 50, 51 We preferred Conners' instruments to other behavioral measures because of their widespread employment in research, and we favored the CPTQ in particular because of its known sensitivity to treatment effects in pharmacotherapy trials. 52 A score of 15 on the CPTQ reasonably discriminates hyperactive from control children. 53 Followup-the amount of time between ingestion of AFCs or placebo, or between initiation of active or placebo diet and outcome measurement-could be of any length.
Search Strategy & Data Abstraction
We searched through OldMedline, MedLine, PubMed, PsychInfo, Digital Dissertations/UMI ProQuest, ToxLine, Current Contents, Biosis, the Cochrane Controlled Trials Register, and EMBASE with combinations of the following keywords: ''hyperactiv#,'' ''hyperkin#,'' ''behav#,'' ''attention deficit,'' ''minimal brain,'' combined with ''color#,'' ''colour#,'' and ''dye.'' We conducted searches with the names of individual AFCs, examined 5 relevant dissertations with extensive bibliographies, 18, 19, [54] [55] [56] and combed trials and reviews for references to other trials. We contacted investigators whose published work otherwise met our inclusion criteria but lacked sufficient information for inclusion.
We developed a form, available from the authors, for recording trials' features relevant to our hypotheses. Adapting the methods of Alderson et al, 57 we graded trials according to the degree that they adequately addressed types of bias and avoided important threats to validity: differential selection, performance, attrition, detection, and reporting.
Statistical Methods
We employed the DerSimonian and Laird random effects model 58 with the standardized mean difference (SMD) as our measure of effect size (ES). The SMD describes the difference in outcome between the active and control arms of a trial in terms of the number of pooled standard deviations by which the two groups differ. Adverse effects on hyperactivity are reflected in positive ES values.
When the SMD could not be calculated directly, we employed conservative statistical techniques to calculate or estimate it. [59] [60] [61] To calculate the variance around the SMD for crossover trials, we employed a method, described in a recent meta-analysis, 62 involving the Pearson productmoment correlation (r) to reflect correlation between individuals' scores in crossover periods. When trials provided insufficient information by which to calculate r, we imputed a value from other trials through standard techniques of combining r values. 63 For trials reporting noncontinuous (e.g., dichotomous) outcomes, we converted these data to the most conservative odds ratio that would fit the data. We then calculated the SMD through methods described by Shadish et al 61 and the variance through a method described by Rosenthal. 64 Our subhypotheses, which propose differences between groups of studies, were tested with weighted analysis of variance, which weights trials' ESs by the inverse of their variance. 65 When the Mantel-Haenszel test of homogeneity demonstrated that within-group statistical homogeneity was unlikely (p < 0.20), we defined ESs as statistically heterogeneous and therefore not combinable. 66, 67 We conducted additional analyses to test the sensitivity of our methods to several assumptions. A funnel plot was created to evaluate the potential for publication bias. The robustness of the results against publication bias was estimated with the fail-safe n. This statistic represents the number of unpublished studies with an ES of zero necessary to reduce a summary ES to a particular value; 68 it assumes the unpublished studies are of similar size to those already published. To calculate our fail-safe n, we chose an ES of 0.15, which, even if statistically significant, would represent a limited threat to an individual's health.
RESULTS
Search Results
Of 2156 references found by electronic search through September, 2002, 427 nonduplicate items were identified as Subjects who contributed data to the primary analysis/total subjects in the trial. c Author operationalized 3 variables: duration the subject spent attending to an assigned task; frequency/duration spent out-of-seat in classroom; and frequency of acts of physical aggression.
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pertinent trials or as potentially containing references to such trials. For our primary analysis, we identified 15 unique double-blind placebo-controlled trials evaluating the behavioral effects of AFCs among subjects whose baseline diagnosis of hyperactivity has been graded ( Table 1 ). The grading roughly reflects the comprehensiveness and rigor of the diagnostic process employed by the trials' investigators. For our secondary analysis, we identified eight additional crossover trials or subsets of trials which otherwise met our inclusion criteria but studied either exclusively nonhyperactive children 69 or heterogeneous groups of children (Table 2) . [70] [71] [72] [73] [74] [75] [76] Two of the latter, 75, 76 enrolling both hyperactive and nonhyperactive children, contribute independent data to both the primary and secondary analyses. A table of excluded trials is available from the authors.
Primary Analysis
Fifteen trials included a total of 219 subjects ( Table 1) . The average age of the subjects was estimated at 7.9 years and the male-to-female ratio at 5.5 to 1. Seven trials explicitly excluded children on medications or discontinued the medications before the beginning of the trial. 75, [77] [78] [79] [80] [81] [82] Of the 219 participants, 136 (62%) entered the double-blind phase of the trials after successful screening for responsiveness to either AFCs or the FD.
All trials were double-blind crossover trials. All trials employed randomization except one, 79 which fixed order of treatment beforehand. Only 5 trials had washout periods, all between 2 and 5 days. 76, 81, [83] [84] [85] Five trials 78, [82] [83] [84] 86 employing the CPTQ provided insufficient information whereby to calculate r for at least 1 set of raters; we imputed a value (0.822) through combination of data from similar relevant trials. 74, 75, 77, 78, [87] [88] [89] This value is consistent with published values as employed in pharmacotherapy trials. 51, [90] [91] [92] Three trials reported outcomes that were dichotomous 76, 85 or trichotomous. 93 Tartrazine and a variety of mixtures of AFCs were the primary interventions in the challenge arms of the trials and were administered through a variety of vectors, such as pills and cookies. Dosages varied widely and, in 8 trials, 75, 77, 78, [81] [82] [83] [84] 94 were split into multiple daily doses. Three trials employed outcome measures that have not been validated. 79, 81, 95 Only 2 trials 82,84 received our highest validity score, ''A.'' Rose's trial 79 received a ''C'' for failure to employ randomization, as described; Rapp's trial 93 received a ''C'' for employing what appeared to us a poorly disguised placebo. Failure to discuss procedures of allocation concealment was the most common mark against the trials.
Secondary Analysis
Eight crossover trials included 132 participants ( Table 2) . The male-to-female ratio was approximately 3.5 and the average age of participants was 7.3. Two of these trials contributed hyperactive patients to our primary analysis. 75, 76 Eighty-four patients (64%) in these trials had been deemed responsive by screening before entry into the blinded trial. Two trials had no wash-out period. 69, 75 Three 
Results
Primary Analysis. The trials' summary ES is 0.283 (95% CI, 0.079 to 0.488), reflecting a change of slightly more than one quarter of a SD (Figure 1) . If we assume a normal distribution of response to AFCs, this change represents a shift from the 50th to the 61st percentile of hyperactivity for the average hyperactive child in the population of trials.
To address our first subhypothesis, we have separated parents', teachers', and clinicians' ratings into 23 ESs (Figure 2) . While health professionals' ratings (ES = 0.107, 95% CI, À0.128 to 0.343) and teachers' ratings (ES = 0.0810, 95% CI, À0.073 to 0.235) are not statistically significant, parents' ratings are (ES = 0.441, 95% CI, 0.161 to 0.721), corresponding to a 17 percentile shift for the average hyperactive child. Despite an apparent reduction in the likelihood of statistical heterogeneity within the groups ( p = 0.506 vs. 0.232 in the unstratified analysis), no statistical difference was found between these three groups' scores (p = 0.674).
To address our second subhypothesis, we compared the group of trials whose subjects had not been screened for responsiveness to AFCs or the FD to the group of trials whose subjects had been screened by either an open trial or parental report. The summary ES of the trials without a criterion of responsiveness demonstrated a statistically nonsignificant ES of 0.090 (95% CI, À0.108 to 0.288). The summary ES of the trials whose subjects had previously demonstrated responsiveness through open trial or parental report had a statistically significant ES of 0.535 (95% CI, 0.149 to 0.920), corresponding to a 20 percentile shift for the average nonhyperactive child screened for responsiveness to AFCs. An additional trial, whose subjects had been screened with a blinded trial of the FD, had a statistically nonsignificant ES of 0.182 (95% CI À.208 to 0.571). Segregation of the trials into three strata, according to their inclusion criteria, appears to reduce within-group statistical heterogeneity (p = 0.448 versus prior p = 0.232), suggesting a more natural grouping of studies. However comparison of the group without a screening criterion to the group that screened through open trial or parental report falls short (p = 0.185) of substantiating a statistically significant difference between these groups.
To begin addressing our third subhypothesis, we ordered trials by the diagnostic grades found in Table 1 . We found no visual trend among their ESs (Figure 1 ). FIGURE 1. The effect sizes from the 15 trials in the primary analysis and their resultant summary effect size. Trials are listed in an order broadly reflecting the comprehensiveness and rigor employed in the assignment of subjects' baseline diagnoses: the diagnostic processes of trials listed further down the page received higher marks, according to the criteria described at the foot of Table 1 . AFC, artificial food color; SMD, standardized mean difference. 
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Secondary Analysis. For the secondary trials, our summary ES of 0.117 (95% CI, À0.113 to 0.347) was not statistically significant. Trials that did not screen for responsiveness demonstrated a statistically nonsignificant response to AFCs (ES = À0.112, 95% CI, À0.393 to 0.169); however, a statistically significant ES of 0.316 (95% CI, 0.157 to 0.475) characterized the trials that did screen through open trial or parental report (Figure 3 ). This ES corresponds to a 12 percentile rank shift in hyperactivity for the average nonhyperactive average child among trials that screened for responsiveness prior to double-blind allocation. The difference in the ESs of screened and unscreened children in the secondary studies is statistically significant (p = 0.022), supporting our second subhypothesis. A post-hoc analysis combining trials from both the primary and secondary analyses suggested that, among all trials, those that screened with open trial or parental report differed significantly from those that did not screen (p = 0.022).
The summary ES of the trials in the secondary analysis, whose participants were predominantly nonhyperactive, did not differ significantly from the summary ES of the trials in the primary analysis, whose participants all had a putative diagnosis of hyperactivity (p = 0.660). Both this fact and the lack of any visual trend in Figure 1 , described above, defy our third subhypothesis that presence of a baseline diagnosis of hyperactivity and rigor of that diagnosis correspond to reactivity to AFCs.
Sensitivity Analysis of Primary Trials. Excluding from our 15 primary trials the 2 trials that received our lowest validity score ''C'' resulted in a smaller but still statistically significant result (ES 0.216, 95% CI, 0.015 to 0.410). Because the random effects model disproportionately gives small trials more weight, we removed the 2 smallest trials, which enrolled only one 83 or two 79 subjects, on the grounds that their positive ESs may have skewed our overall results. The summary ES was reduced to 0.255 (95% CI, 0.043 to 0.467), but the hypothesis of statistical homogeneity was rejected (p = 0.179) in this one analysis. However, when we implemented both prior conservative manipulations, the assumption of homogeneity was restored, achieving a result that is smaller but of similar magnitude and statistically significant (cf. Table 3 ). Because of concern that imputation of too large a value of the product-moment correlation coefficient (r) would reduce trials' variance and therefore artificially narrow their confidence intervals, we retested our primary model by reducing the coefficient to 0.500 in the five trials that required imputation of the coefficient. This maneuver raised the ES to 0.371 with only a slight widening of the confidence interval (95% CI, 0.0953 to 0.647).
The absence of trials from the lower left-hand corner of our funnel plot (Figure 4 ) corresponds to possible publication bias against small trials with negative ESs. Given a calculated summary ES of 0.283, the fail-safe n for an ES of 0.15 is 13.30, which is almost as many studies as were actually published.
DISCUSSION
Our meta-analysis supports the hypothesis that AFCs promote hyperactivity in hyperactive children, as measured on behavioral rating scales. This, our central result, would appear to conflict with a relevant subanalysis in a prior meta-analytic evaluation of elimination diets. In that subanalysis, Kavale and Forness 42 examined trials challenging subjects with foodstuffs excluded from the FD. Their calculated ES was only 0.045 (95% CI, À0.046 to 0.136), in contrast to our larger ES of 0.283 (95% CI, À0.079 to 0.488). However, in their analysis, the evaluated interventions were not limited to AFCs but also included other substances which may have different, if any, effects on hyperactivity. Additionally, our primary analysis included four trials that theirs did not: two trials that they overlooked 79, 95 and two trials published subsequent to their analysis. 76, 85 Three of these trials were large, increasing the power of our meta-analysis. Additionally, we enhanced our power by employing the statistical technique of Jennings et al 62 that acknowledges the reduction of statistical variance in crossover trials.
In our sensitivity analysis, removing trials of questionable validity and challenge of our statistical assumptions did not appreciably change the magnitude of the summary ES or its statistical significance. The magnitude of this ES is approximately a third to a half the magnitude of the ESs calculated in a meta-analysis of trials evaluating methylphenidate as a treatment of ADHD. 96 Therefore, the extent of behavioral deterioration posed by AFCs may be understood as a third to a half of what might be observed when hyperactive children are taken off their psychostimulants.
Our first subhypothesis, that parents, teachers and clinicians differ in their reports of hyperactivity, could not be confirmed: the three groups' individual ESs did not statistically differ. Although the summary ES of each of the three groups was positive, the finding that only the parents' 
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summary ES was statistically significant deserves explanation. Because crossover trials enable subjects to compare the two phases, unblinding on the part of the parents, who often administer the intervention, could explain these results. However, all investigators who rigorously tested the blinding [77] [78] [79] 82, 83 confirmed that the subjects, their parents or the investigators were unable to guess beyond chance the identity of the interventions.
The characteristics of particular rating scales may be the prisms through which to understand parents' penchant for higher scoring in our trials. First, one trial, 76 whose ES was the largest of those we calculated, measured outcome with a scale reflecting parental reports of symptoms suspected to result from AFC ingestion. This scale, the Rowe Behavioral Research Inventory, emphasizes irritability and sleeplessness, both of which may be particularly disruptive to the parent-child dyad, and de-emphasizes restlessness and attentional difficulties, which are of particular concern to teachers. Second, Weiss et al 69 reported a very small probability ( p = 1.6 Â 10 À5 ) that chance accounted for one particular child's pattern of responsiveness to AFCs. Their trial employed a different outcome scale for each subject tailored to symptoms preselected by the child's parents from standardized rating scales. Third, Mattes and GittelmanKlein, 83 who found no change on the CPTQ in their singlesubject multiple-crossover design, conceded that this scale did not capture the irritability consistently noted by the subject's mother while the subject was receiving the active intervention. These examples suggest several reasons why parents may have detected behavioral change unnoticed by teachers and clinicians: parents' concerns may differ from those of teachers and clinicians; parents may be particularly attuned to the idiosyncrasies of their own children; and AFCs may promote a pattern of symptoms that is incongruent with modern criteria for ADHD but that is nevertheless bothersome to parents.
Our second subhypothesis, that children potentially responsive to AFCs can be identified through screening methods, was partially substantiated by our analysis. As a SMD, standardized mean difference; CI, confidence interval; DF, degrees of freedom for within-group Q; Q w, Q total for preceding strata; FD, Feingold Diet.
a Chi-distribution is not defined for zero DF, but probability of statistical heterogeneity in a stratum of one trial is 0.00 (p = 1.00). 
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group, trials that screened for responsiveness demonstrated a statistically significant effect whether enrolling hyperactive or heterogeneously diagnosed, predominantly nonhyperactive subjects. However, we found a statistically significant difference between trials that screened and those that did not only among the group of trials enrolling heterogeneous subjects predominantly without hyperactivity. Screening may be more effective in heterogeneous populations because of greater variability in responsiveness to AFCs among such populations than among the strictly hyperactive populations. Our third subhypothesis could not be confirmed. There was no statistically significant difference between the ESs of trials enrolling hyperactive children and the ESs of trials enrolling predominantly or exclusively nonhyperactive children. Even among the group of trials enrolling hyperactive children, rigor of diagnosis did not correspond to reactivity to AFCs, suggesting that AFC-sensitivity among patients may not be limited to those with clear-cut, criteria-specific hyperactive syndromes. That we were able to find an overall statistically significant ES for our primary analysis but not for our secondary analysis generally corresponds to evidence from prior studies demonstrating that hyperactive children have physiologic responses to AFCs not found in controls. [44] [45] [46] Most trials evaluated in this meta-analysis employed methods and designs that may potentially underestimate the effect of AFCs. First, the crossover design is appropriate only when effects do not carry over between periods. Rowe found that the effect of AFC challenges carried over in rating scales for 3-4 days in one child, while in another child 3.5 weeks, 73 suggesting that the washout periods used in most trials may have been inadequate. Second, several investigators have demonstrated that objective measures of learning and attention are adversely affected within two hours of AFC administration, suggesting that too much time may have elapsed between administration of AFCs and measurement of outcomes. 23, 80, 97 Third, as several investigators evaluated dosages well below children's true likely daily exposure, 98 one must consider whether the real-world effects of AFCs are greater than the effects captured in our trials.
Several limitations, especially of the included trials, but also of our meta-analytic methods, restrict the interpretation of our results. First, the use of unorthodox scales to measure behavioral responses may limit the validity of conclusions drawn about the effects of AFCs on hyperactivity. However, while the standard CPTQ was developed as a simplified measure of childhood behavior suggesting a diagnosis of hyperactivity, its specificity in distinguishing hyperactivity from global psychopathology has also been questioned. 52 The likelihood that the multiple versions of Conners' instruments measure slightly different underlying behavioral constructs 52 further challenges the specificity of our findings. Consequently, the trials included in the present study may effectively implicate AFCs more in provoking general behavioral disturbance than in exacerbating criteriaspecific hyperactive symptomatology.
Second, many of the trials employ statistical methods that do not distinguish between normally distributed reactivity and large idiosyncratic reactions confined to a few individuals. Several investigators noted that positive group effects are often attributable to the profound response of a few individuals, while conclusions about a lack of group effects may overlook considerable individual response. 34, 69 Third, our funnel plot raises the possibility of publication bias against small trials with negative results. However, the fail-safe n demonstrates that discovery of a considerable number of unpublished studies would be required to reduce our summary ES to a trivial value. Confidence in our overall result is further suggested by our sensitivity analysis, which demonstrates that our results are internally robust.
Finally, clinical heterogeneity may limit the interpretability of our results. We attempted to address clinical heterogeneity by segregating trials which screened for responsiveness to AFCs from those that did not by differentiating between trials which enrolled hyperactive and heterogeneous populations, and by considering whether formal assignment of diagnoses predicted responsiveness. Although tests of statistical heterogeneity suggest that results were statistically combinable, a larger number of trials, especially with more detailed data, would have given us greater power to aggressively address many clinical differences in trials, such as types and dosages of AFCs, timing and choice of outcome measurements, and enrollment of the various subtypes within the hyperactivity spectrum. Trials' inconsistent reporting of subtypes prevents us from retiring an important question: whether the trials' and our study's focus on behavioral outcomes makes our study irrelevant to ADHD's inattentive subtype, whose symptoms may not be predominantly behavioral phenomena.
Despite these limitations, our results strongly suggest an association between ingestion of AFCs and hyperactivity. We believe this is the first comprehensive quantitative analysis of trials addressing the effects of AFCs on hyperactivity. Prior reviews and the only meta-analysis in field of elimination diets have attempted to address this issue but our critical review differs in several ways. We have focused on AFCs in particular rather than the FD as a whole. Compared to the prior meta-analysis by Kavale and Forness, 42 ours employs hypotheses that are more explicit, inclusion criteria that are more rigorous, and a search that is now more current and also more comprehensive. Consequently, we have included only double-blind placebocontrolled trials. Our primary and secondary analyses include 2 trials 79,95 that Kavale and Forness overlooked and 6 trials [71] [72] [73] [74] 76, 85 subsequent to their analysis. In addition, as noted, our statistical techniques more richly exploit the advantages of crossover trials. Furthermore, our more explicit sensitivity analysis and our evaluation of publication bias afford a previously unwarrantable confidence: that any conclusions drawn about the relevant body of literature do not unduly depend on the influence of a few unrepresentative trials. Finally, our evaluation of our subhypotheses has identified areas to be examined and methods to be employed in future research.
Closer characterization of the response to AFCs than we currently have requires studying responders. We have demonstrated that screening through parental report and open trial may aid in identifying such responders. Other research has hinted that electroencephalography 99 and measurement of simple physiologic parameters 44 could aid in the identification of these responders. Combining these tools could focus investigators' efforts on a more targeted population and could reduce the number of nonresponders subjected to long, complex blinded trials. However, we have also shown that researchers should not limit their search for responders to those previously diagnosed with hyperactivity.
In our results, parents tended to detect greater change from the intervention than did teachers. This tendency contrasts that of pharmacotherapy trials, in which teachers' ratings have generally been higher, probably because common dosing schedules optimize children's behavior during the school day. 96 Future research on AFC-induced behavioral disturbance should acknowledge how timing of interventions may affect the ratings of parents, teachers and clinicians. Research should maximize these groups' attunement to particular symptoms, as was done by Weiss et al, whose scales reflect parental concerns. 69 Finally, we advocate for the continuing development of scales which address the particular symptoms that AFCs may cause, such as the insomnia and irritability noted by several investigators. 73, 76 Such research may lead investigators out of the realm of hyperactivity and into a wider province of behavioral pathology.
We also recommend that crossover designs be avoided until the pharmacokinetics of AFCs are better understood. The effect of interactions of AFCs with foods and medications should also to be explored. Finally, we recommend that future research avoid the pitfalls of many prior trials by explicitly identifying subjects' demographic characteristics; by employing specific diagnostic criteria and by identifying diagnostic subtypes and comorbidities; by identifying the concurrent use of medications; by specifying the interval between administration of AFCs and measurement of effect; by administering specific AFCs rather than mixtures; by explicitly testing the blinding of subjects; and by reporting all such information in published reports.
Given the need for additional research, we are cautious about making clinical recommendations at this time. On the one hand, parental preference for nonpharmacologic treatment 100 must be acknowledged and, in many cases, accommodated, if the clinician's relationship with a patient's parents is to be preserved. 9 On the other hand, the restrictiveness of an AFC-free diet may burden hyperactive children, who are already at risk for poor psychosocial outcomes. 101 Therefore, imposition of the diet should be done reluctantly until more certain methods have been developed to identify who is AFC-responsive.
Basic questions about the biology of AFCs remain unanswered, including whether children's responses to AFCs depend more on an allergic or a pharmacological mechanism. 99, 102, 103 Tartrazine and its metabolites, for example, may act through both. 102 Clarification of the mechanism of response will deepen understanding of the possibility that responses are not normally distributed.
Neurochemical research into the basis of ADHD has strongly implicated defects in dopamine transmission. Both dopamine depletion and administration of AFCs create hyperactivity in developing rats. 13 However, a theory on the contribution of AFCs to ADHD symptomatology must contend with two incongruities. First, the symptomatology of ADHD may differ from the pattern of symptoms induced by AFCs: as suggested by Rowe and Rowe, 76 AFCs are associated more with irritability and insomnia than restlessness and inattention. Second, the patterns of behavior elicited by dopamine depletion in developing rats differs from the pattern elicited by administration of AFCs (or their metabolites). The sensitivity of developing rats also begs consideration of whether exposure to AFCs differentially affects the developing and developed organism.
Given how little we know about the neurochemical effects of AFCs, we endorse prior recommendations that assessment of behavioral toxicity should be a part of food additive evaluation. 33 The increasing recognition of subclinical neurobehavioral toxicity of low doses of several environmental toxins, especially among developing children, [104] [105] [106] demands ambitious vigil against avoidable harmful exposures. At the very least, regulators should track consumption of AFCs; we know only that domestic production of food dyes quadrupled between 1955 and 1998. 25 Finally, as long as we remain uncertain about the early and long-term effects of these exposures, society should engage in a broader discussion about whether the aesthetic and commercial rationale for the use of AFCs is justified. 107 
